Skip to main content

Table 4 Rejection, infection, and other outcomes

From: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation

  ATG (n = 15) DZM (n = 15) p value
Mean biopsy grade 0.4 0.3 0.09
Patients experiencing rejection 2 (13%) 0 0.5
Total number of acute rejections 2 0 0.2
Time to first rejection episode (days) 84 - -
Patients experiencing infection 10 (67%) 10 (67%) 1.0
Total number of infections 25 21 0.7
Infections/patient 1.7 1.4 0.7
Patients experiencing severe infection 4 (27%) 5 (33%) 1.0
Number of severe infections 7 7 1.0
Severe infections/patient 0.5 0.5 1.0
Number of CMV infections 1 2 1.0
Malignancy 0 1 1.0
Steroid-induced diabetes 2 2 1.0
Re-transplant 0 0 -
ICU length of stay (days) 11 ± 4 12 ± 4 09
Total hospital length of stay (days) 29 ± 8 27 ± 6 0.8
One-month survival 93% 100% 0.1
One-year survival 87% 87% 0.1
\